David R. Md Leeds

David R. Md Leeds

Auto-generated profile, based on publicly available information

David R. Md Leeds

Boston University School of Medicine, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2022 in Medicine
Verified
Journal Article
Open access
SZSarah Zambrano
Sarah Zambrano
MDMegan Davis
Megan Davis
DLDavid R. Md Leeds
David R. Md Leeds
KNKelvin Noronha
Kelvin Noronha
AMAngela MD McLaughlin
Angela MD McLaughlin
SASabrina Assoumou
Sabrina Assoumou
Early identification of patients at risk for severe coronavirus disease 2019 (COVID-19) is crucial for appropriate triage and determination of need for closer monitoring. Few studies have examined laboratory trends in COVID-19 infection and sought to quantify the degree to which laboratory values affect mortality. We conducted a retrospective cohort (n = 407) study of hospitalized patients with COVID-19 early in the course of the pandemic, from March 16th to April 8th, 2020 and compared baseline to repeat laboratory testing 72 hours into admission. The primary outcome was death. We found that rises of 25 mg/L C-reactive protein, 50 units/L lactate dehydrogenase, and 100 ng/mL ferritin were associated with 23%, 28%, and 1% increased odds of death, respectively. In contrast, changes in fibrinogen, D-dimer, white blood cell count, and creatinine in the first few days of hospital admission were not associated with mortality. These quantitative findings may assist clinicians in determining the risk of potential clinical decline in patients with COVID-19 and influence early management.